Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antiaging Quantum Living Inc AAQL

Antiaging Quantum Living Inc. is an investment holding company. It focuses on Website development, maintenance and online business advertisement. Its primary business operations are conducted through its subsidiaries AAQL Inc., AAQL HK Limited, Antiaging Doctor Hangzhou Holding LTD (Dao Ling Doctor Hangzhou), Dao Ling Doctor (Zhejiang) Health Management Limited (Dao Ling Doctor Zhejiang), and... see more

Recent & Breaking News (OTCPK:AAQL)

Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference

GlobeNewswire February 13, 2017

The Market In 5 Minutes: Facebook Beats, Trump Tweets

Benzinga.com  February 2, 2017

Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy

Benzinga.com  February 2, 2017

Mid-Afternoon Market Update: Derma Sciences Climbs On Acquisition News; Novadaq Shares Plunge

Benzinga.com  January 11, 2017

Mid-Day Market Update: Crude Oil Up 2.5%; Ethan Allen Shares Drop On Weak Forecast

Benzinga.com  January 11, 2017

Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV

GlobeNewswire December 28, 2016

18 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  December 19, 2016

Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases

GlobeNewswire December 5, 2016

Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV

GlobeNewswire November 30, 2016

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire November 14, 2016

Biotech Stocks Under Scanner -- Anavex Life Sciences, Eleven Biotherapeutics, Achillion Pharma, and Tokai Pharma

PR Newswire November 11, 2016

20 Biggest Mid-Day Losers For Thursday

Benzinga.com  November 3, 2016

Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology

GlobeNewswire November 3, 2016

Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs

GlobeNewswire November 3, 2016

Achillion to Present at the Credit Suisse 25th Annual Healthcare Conference

GlobeNewswire November 2, 2016

Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV

GlobeNewswire September 23, 2016

Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV

GlobeNewswire September 9, 2016

Watch These 7 Huge Call Purchases In Wednesday Trade

Benzinga.com  September 7, 2016

Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop

GlobeNewswire September 6, 2016

Achillion to Present at Two Upcoming Investor Conferences

GlobeNewswire September 1, 2016